Utility of the CAT in the therapy assessment of COPD exacerbations in China

BMC Pulmonary Medicine

Guang-He Fei¹  Yan Zhang¹  You-Hui Tu¹ 

[1] Pulmonary Department, First Affiliated Hospital of Anhui Medical University, Hefei, 230022 Anhui, China

关键词: Therapy assessment;    Pulmonary function;    Inflammatory biomarkers;    Exacerbation;    Chronic obstructive pulmonary disease assessment test;   

Others  :  866462
DOI  :  10.1186/1471-2466-14-42

 received in 2013-06-23, accepted in 2014-03-07,  发布年份 2014

【 摘 要 】

Background

Chronic obstructive pulmonary disease (COPD) exacerbations are accompanied with increased systemic inflammation, which accelerate the pulmonary function injury and impair the quality of life. Prompt and effective treatments for COPD exacerbations slow down the disease progression, but an objective instrument to assess the efficacy of the treatments following COPD exacerbations is lacking nowadays. The COPD Assessment Test (CAT) is an 8-item questionnaire designed to assess and quantify health status and symptom burden in COPD patients. We hypothesize that the change in CAT score is related to the treatment response following COPD exacerbations.

Methods

78 inpatients with clinician-diagnosed acute exacerbation of COPD (AECOPD) completed the CAT, St George’s Respiratory Questionnaire (SGRQ) and modified Medical Research Council (mMRC) Dyspnea Scale both at exacerbation and the 7th day of therapy, and a subgroup of 39 patients performed the pulmonary function test. Concentrations of serum C-reactive protein (CRP) and plasma fibrinogen were assayed at the same time. Correlations between the CAT and other measurements were examined.

Results

After 7 days’ therapy, the CAT and SGRQ scores, mMRC grades, as well as the concentrations of CRP and fibrinogen all decreased significantly (P < 0.001). Meanwhile, the FEV1% predicted had a significant improvement (P < 0.001). The CAT scores were significantly correlated with concurrent concentrations of CRP and fibrinogen, SGRQ scores, FEV1% predicted and mMRC grades (P < 0.05). The change in CAT score was positively correlated with the change of CRP (r = 0.286, P < 0.05), SGRQ score (r = 0.725, P < 0.001) and mMRC grades (r = 0.593, P < 0.001), but not with fibrinogen (r = 0.137, P > 0.05) or FEV1% predicted (r = -0.101, P > 0.05). No relationship was found between the changes of SGRQ score and CRP and fibrinogen (P>0.05).

Conclusions

The CAT is associate with the changes of systemic inflammation following COPD exacerbations. Moreover, the CAT is responsive to the treatments, similar to other measures such as SGRQ, mMRC dyspnea scale and pulmonary function. Therefore, the CAT is a potentially useful instrument to assess the efficacy of treatments following COPD exacerbations.

【 授权许可】

   
2014 Tu et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Fang X, Wang X, Bai C: COPD in China: the burden and importance of proper management. Chest 2011, 139(4):920-929.
• [2]Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez- Roisin R: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013, 187(4):347-365.
• [3]Wedzicha JA, Donaldson GC: Natural history of successive COPD exacerbations. Thorax 2012, 67(11):935-936.
• [4]Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA: Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157:1418-1422.
• [5]Gross NJ: Outcome measures for COPD treatments: a critical evaluation. COPD 2004, 1(1):41-57.
• [6]Jones PW, Harding G, Wiklund I: Improving the process and outcome of care in COPD: development of a standardised assessment tool. Prim Care Respir J 2009, 18:208-215.
• [7]Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy NK: Development and first validation of the COPD assessment test. Eur Respir J 2009, 34(3):648-654.
• [8]CAT development steering group: COPD assessment test-healthcare professional user guide http://www.catestonline.org webcite
• [9]Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, Perez T, Soler Cataluña JJ, van der Molen T, Adamek L, Banik N: Properties of the COPD assessment test in a cross-sectional European study. Eur Respir J 2011, 38:29-35.
• [10]Marchand E, Maury G: Evaluation of the COPD assessment test in patients with stable COPD. Rev Mal Respir 2012, 29(3):391-397.
• [11]Kelly JL, Bamsey O, Smith C, Lord VM, Shrikrishna D, Jones PW, Polkey MI, Hopkinson NS: Health status assessment in routine clinical practice: the chronic obstructive pulmonary disease assessment test score in outpatients. Respiration 2012, 84(3):193-199.
• [12]Jones PW, Harding G, Wiklund I, Berry P, Tabberer M, Yu R, Leidy NK: Tests of the responsiveness of the COPD assessment test following acute exacerbation and pulmonary rehabilitation. Chest 2012, 142(1):134-140.
• [13]Mackay AJ, Donaldson GC, Patel AR, Jones PW, Hurst JR, Wedzicha JA: Usefulness of the chronic obstructive pulmonary disease assessment test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med 2012, 185(11):1218-1224.
• [14]Wiklund I, Berry P, Lu KX: The Chinese translation of COPD assessment test (CAT) provides a valid and reliable measurement of COPD health status in Chinese COPD patients. Am J Respir Crit Care Med 2010, 181:A3575.
• [15]Perera WR, Hurst JR, Wilkinson TMA, Sapsford RJ, Mullerova H, Donaldson GC, Wedzicha JA: Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007, 29(3):527-534.
• [16]Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, Jeffries DJ, Meade TW: Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000, 84(2):210-215.
• [17]Wedzicha JA, Donaldson GC: Exacerbations of chronic obstructive pulmonary disease. Respir Care 2003, 48(12):1204-1213.
• [18]Quint JK, Donaldson GC, Hurst JR, Goldring JJ, Seemungal TR, Wedzicha JA: Predictive accuracy of patient-reported exacerbation frequency in COPD. Eur Respir J 2011, 37:501-507.
• [19]van Eeden SF, Sin DD: Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease. Respiration 2008, 75:224-238.
• [20]Garcia-Rio F, Miravitlles M, Soriano JB, Muñoz L, Duran-Tanuleria E, Sánchez G, Sobradillo V, Ancochea J: Systemic inflammation in chronic obstructive pulmonarydisease: a population-based study. Respir Res 2010, 11(1):63. BioMed Central Full Text
• [21]Doyle TJ, Pinto-Plata V, Morse D, Celli BR, Rosas IO: The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases. Chest 2012, 142:1027-1034.
• [22]Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Biello JA, Hagan GW, Vessey RS, Wedzicha JA: Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 174(8):867-874.
• [23]Dickens JA, Miller BE, Edwards LD, Silverman EK, Lomas DA, Tal-Singer R, Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) study investigators: COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res 2011, 12:146. BioMed Central Full Text
• [24]Murphy TF: The role of bacteria in airway inflammation in exacerbations of chronic obstructive pulmonary disease. Curr Opin Infect Dis 2006, 19:225-230.
• [25]Wedzicha JA: Role of viruses in exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004, 1:115-120.
• [26]Snoeck-Stroband JB, Postma DS, Lapperre TS, Gosman MM, Thiadens HA, Kauffman HF, Sont JK, Jansen DF, Srerk PJ: Airway inflammation contributes to health status in COPD: a cross-sectional study. Respir Res 2006, 7(1):140. BioMed Central Full Text
• [27]Mohan A, Prasad D, Sharma A, Arora S, Guleria R, Sharma SK, Pandey RM: Delayed resolution of inflammatory response compared with clinical recovery in patients with acute exacerbations of chronic obstructive pulmonary disease. Respirology 2012, 17(7):1080-1085.
• [28]Tsiligianni IG, van der Molen T, Moraitaki D, Lopez I, Kocks JW, Karagiannis K, Siafakas N, Tzanakis N: Assessing health status in COPD. A head-to-head comparison between the COPD assessment test (CAT) and the clinical COPD questionnaire (CCQ). BMC Pulm Med 2012, 12:20. BioMed Central Full Text
• [29]Dodd JW, Hogg L, Nolan J, Jefford H, Grant A, Lord VM, Falzon C, Garrod R, Lee C, Polkey MI, Jones PW, Man WDC, Hopkinson NS: The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study. Thorax 2011, 66(5):425-429.
• [30]Dodd JW, Marns PL, Clark AL, Ingram KA, Fowler RP, Canavan JL, Patel MS, Kon SS, Hopkinson NS, Polkey MI, Jones PW, Man WD: The COPD assessment test (CAT): short and medium-term response to pulmonary rehabilitation. COPD 2012, 9(4):390-394.
• [31]Zhou QT, Mei JJ, He B, Huang SG, Wen FQ, Zhao MW: Chronic obstructive pulmonary disease assessment test score correlated with dyspnea score in a large sample of Chinese patients. Chin Med J (Eng) 2013, 126(1):11-15.
• [32]Jones PW, Adamek L, Nadeau G, Banik N: Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification. Eur Respir J 2013, 42(3):647-654.
• [33]Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA: Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 161(5):1608-1613.
• [34]Halpin DM, Decramer M, Celli B, Kesten S, Dacheng L, Tashkin DP: Exacerbation frequency and course of COPD. Int J Chro Obstruct Pulmon Dis 2012, 7:6.